TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
The company has tied up with OrbiMed as a financial partner for global reach
The profits were bolstered by the Boehringer Ingelheim MEK program income
Formulation business grew by 15 per cent in the quarter
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
A globally approved pen filled by mass technology provides a safer self- administration fertility solution
Company working on COVID vaccine INO 4800
A veteran in cell therapy and oncology commercialisation
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
Subscribe To Our Newsletter & Stay Updated
